All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Poor health-related quality-of-life (HRQOL) is a significant public health issue. For example, in the United States (US), the age-adjusted prevalence of adults 18 years of age and older who rated their health as fair or poor was estimated to be 16.1% \[[@pone.0129181.ref001]\]. Meditative movement therapies (MMT) such as yoga, tai chi and qigong have become increasingly popular and offer a potential approach for improving HRQOL in adults. In 2007, the age-adjusted prevalence of US adults ages 18 years and older who participated in yoga (12.8 million), tai chi (2.1 million), and qigong (1 million) totaled approximately 15.9 million, an increase of approximately 2 million when compared to 2002 data \[[@pone.0129181.ref002]\].

Systematic reviews with meta-analysis are considered to be the gold standard for determining the effects of an intervention on an outcome \[[@pone.0129181.ref003],[@pone.0129181.ref004]\]. However, a number of previous systematic reviews with meta-analysis now exist on the same topic \[[@pone.0129181.ref005],[@pone.0129181.ref006]\]. As a result, it becomes difficult to make confident decisions about the effectiveness of an intervention on a chosen outcome in the population of interest \[[@pone.0129181.ref005],[@pone.0129181.ref007]\]. Consequently, it is now necessary to systematically review these previous reviews in order to provide decision-makers and practitioners with the information needed to make evidence-based decisions and recommendations regarding the effects of an intervention on an outcome as well as provide investigators with suggestions for future inquiry \[[@pone.0129181.ref005],[@pone.0129181.ref007]\]. To the best of the investigative team's knowledge, no previous systematic review of systematic reviews with meta-analysis addressing the effects of MMT (yoga, tai chi and qigong) on HRQOL in adults has been conducted. The purpose of this study was to address this gap.

Methods {#sec002}
=======

Study Eligibility {#sec003}
-----------------

This systematic review of previous systematic reviews with meta-analysis is registered in the PROSPERO trial registry (CRD42014014576). Given that no guidelines currently exist for conducting systematic reviews of previous systematic reviews with meta-analysis, the general guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Statement \[[@pone.0129181.ref008]\], where applicable, was followed. Finally, the methods described below have been previously reported in detail on a different topic addressing the effects of aerobic and strength training exercise on depressive symptoms in adults with arthritis and other rheumatic disease \[[@pone.0129181.ref007]\].

The *a priori* inclusion criteria for this study were as follows: (1) previous systematic reviews with meta-analysis of randomized controlled intervention trials or data reported separately for randomized controlled trials if the meta-analysis included other study designs, (2) adults 18 years of age and older, (3) yoga, tai chi or qigong as the intervention, (4) published and unpublished (dissertations and master's theses) studies in any language up through February of 2014, (5) intervention minus control group difference in HRQOL as a primary outcome in the original meta-analysis and reported as the standardized mean difference (SMD) effect size or calculable using the SMD with at least two pooled studies. Meta-analyses were limited to randomized controlled trials because they are the only way to control for unknown confounders as well as the fact that nonrandomized controlled trials tend to overestimate the effects of treatment in healthcare interventions \[[@pone.0129181.ref009],[@pone.0129181.ref010]\]. Given the different instruments used to assess HRQOL, the SMD was the metric of choice. Any studies that did not meet all of the above criteria were excluded. Ineligible studies were excluded based on one or more of the following: (1) inappropriate population (for example, children), (2) inappropriate intervention (for example, aerobic exercise), (3) inappropriate comparison (for example, yoga versus drug), (4) inappropriate outcome (for example, depression), (5) inappropriate study type (for example, systematic review without meta-analysis).

Data Sources {#sec004}
------------

The graphical-user interfaces of the following nine electronic databases were searched from their inception forward for potentially eligible studies: (1) PubMed (1966 to February 26, 2014), (2) Sport Discus (1975 to February 26, 2014), (3) Web of Science (1955 to February 26, 2014), (4) Scopus (1823 to February 27, 2014), (5) PsychInfo (1800's to February 27, 2014), (6) Cochrane Database of Systematic Reviews (1996 to February 26, 2014), (7) Physiotherapy Evidence Database \[(PEDRO) (1929 to March 20, 2014)\], (8) Database of Abstract of Reviews of Effects \[(DARE) (1991 to February 27, 2014\], (9) Proquest (1861 to February 28, 2014). Scopus was included in the database searches because it has been reported to provide coverage of EMBASE, a database that was not available to the investigators \[[@pone.0129181.ref011]\]. While the specific search strategies varied depending on the database searched, key terms or forms of key terms included yoga, tai chi, qigong, quality of life, randomized, systematic review and meta-analysis. A copy of the search strategies used for each database is shown in [S1 File](#pone.0129181.s001){ref-type="supplementary-material"}. After removing duplicates, the overall precision of the searches was calculated by dividing the number of studies that met the eligibility criteria by the total number of studies screened \[[@pone.0129181.ref012]\]. The number needed to read (NNR) was then calculated as the inverse of the precision \[[@pone.0129181.ref012]\]. In addition to electronic database searches, cross-referencing for potentially eligible meta-analyses from retrieved reviews was also conducted. All studies were stored in Reference Manager, version 12.0 \[[@pone.0129181.ref013]\].

Study Selection {#sec005}
---------------

All studies were selected by both authors, independent of each other. They then met and reviewed their selections for agreement. Any disagreements were resolved by consensus.

Data Abstraction {#sec006}
----------------

Prior to data abstraction, coding sheets were developed in Microsoft Excel 2010 \[[@pone.0129181.ref014]\]. The coding sheets could hold up to 180 items from each included meta-analysis. The major categories of variables coded included (1) study characteristics (source, year, etc.), (2) participant characteristics (age, gender, condition, etc.), (3) intervention characteristics (length, frequency, duration, setting, type of MMT, etc.), and (4) results for HRQOL (mean change, precision, z-scores, heterogeneity, inconsistency, publication bias, etc.) Data was abstracted by both authors, independent of each other. Upon completion of coding, all coding sheets were merged into one common codebook and reviewed by both authors for correctness. Disagreements were resolved by consensus. Using Cohen's kappa statistic \[[@pone.0129181.ref015]\], the overall agreement rate prior to correcting discrepancies was *k* = 0.95, considered to be "excellent" \[[@pone.0129181.ref016]\].

Methodological Quality {#sec007}
----------------------

The Assessment of Multiple Systematic Reviews (AMSTAR) Instrument was used to assess the methodological quality of each included meta-analysis \[[@pone.0129181.ref017]--[@pone.0129181.ref020]\]. The AMSTAR instrument was chosen over others \[[@pone.0129181.ref021],[@pone.0129181.ref022]\] because of its reported construct validity (intra-class correlation coefficient = 0.84), inter-rater reliability (*k* = 0.70) and feasibility (average of 15 minutes per study to complete) \[[@pone.0129181.ref019]\]. The 11-item questionnaire is designed to elicit responses of "Yes", "No", "Can't Answer", or "Not Applicable". The response "Can't Answer" is chosen when an item is relevant but not described. The response "Not Applicable" is chosen when an item is not relevant (for example, assessment of publication bias not possible because of the lack of studies) \[[@pone.0129181.ref017]--[@pone.0129181.ref020]\]. For consistency when summing responses, the following question was modified from "Was the status of publication (i.e. grey literature) used as an inclusion criterion?" to "Was the status of publication (i.e. grey literature) as an inclusion criterion avoided?" Both authors assessed the methodological quality of each study independent of each other. They then met and reviewed every item for agreement. Disagreements were resolved by consensus. The overall agreement rate prior to correcting discrepancies was *k* = 0.80, considered to be "excellent" \[[@pone.0129181.ref016]\]. The use of a strength of evidence instrument such as the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool \[[@pone.0129181.ref023]\] was avoided based on the belief that it may be too conservative, especially for an intervention such as MMT where the chance of adverse events is probably minimal.

To assess the impact of the included meta-analyses, the total number of times that each included meta-analysis was cited as well as the average number of citations per year was estimated. This was accomplished using version 4.4.6 of Publish or Perish (Google Scholar Citation mechanism) \[[@pone.0129181.ref024]\] on August 24, 2014.

Data Synthesis {#sec008}
--------------

The main results from each meta-analysis were extracted with a focus on random-effects models because they incorporate between-study heterogeneity into the model \[[@pone.0129181.ref025],[@pone.0129181.ref026]\]. The SMD, 95% confidence intervals (CIs) and associated z and alpha value for z were abstracted or calculated if sufficient data were available to do so. Standardized mean differences were classified as trivial (\<0.20), small (0.20 to 0.49), medium (0.50 to 0.79) or large (≥0.80) \[[@pone.0129181.ref027]\]. Non-overlapping 95% CIs were considered statistically significant. The Q statistic, a measure of heterogeneity, was also extracted for each outcome. An alpha value ≤ 0.10 was considered to represent statistically significant heterogeneity \[[@pone.0129181.ref028]\]. Because of issues surrounding the power of the Q statistic, the *I* ^*2*^ statistic, a measure of inconsistency, was also reported if it was provided in the meta-analysis. If *I* ^*2*^ was not reported, it was calculated if sufficient data was available \[[@pone.0129181.ref028]\]. I-squared values were classified as low (0 to \<25%), moderate (25 to \<50%), large (50 to \<75%) or very large (≥ 75%) inconsistency \[[@pone.0129181.ref028]\]. An *a priori* decision was made to not pool results from the different meta-analyses because of the expectation that many of the same original studies would be included in the different meta-analyses, thus violating the assumption of independence.

An *a priori* assumption was made that none of the eligible meta-analyses would include 95% prediction intervals (PIs) \[[@pone.0129181.ref029]--[@pone.0129181.ref031]\]. Therefore, PIs were calculated if the findings were statistically significant and the necessary data from each study included in each meta-analysis were provided \[[@pone.0129181.ref029]--[@pone.0129181.ref031]\]. Prediction intervals are used to estimate the treatment effect in a new trial \[[@pone.0129181.ref029]--[@pone.0129181.ref031]\] and may be more appropriate for decision analysis \[[@pone.0129181.ref032]\].

In order to reinforce practical application, the number-needed-to treat (NNT) was calculated for any overall findings that were reported as statistically significant. This was achieved using the method suggested by the Cochrane Collaboration and was based on a control group risk of 30% \[[@pone.0129181.ref003]\]. In addition, Cohen's U~3~ index was used to determine the percentile gain in the intervention group \[[@pone.0129181.ref033]\]. For example, a SMD of 0.25 suggests that on average, a person in the MMT group would be at approximately the 60^th^ percentile in terms of improving their HRQOL. This translates into being approximately 10 percentiles higher than the control group \[[@pone.0129181.ref034]\].

If not already provided and if sufficient data and number of effect sizes (N ≥ 10) were available to do so \[[@pone.0129181.ref035]\], small-study effects (publication bias, etc.) were assessed using the regression-intercept approach of Egger et al. \[[@pone.0129181.ref036]\]. Non-overlapping, one-tailed 95% CIs were considered to be representative of statistically significant small-study effects. Positive SMD's were indicative of improvements in HRQOL. Analyses were carried out using Comprehensive Meta-Analysis (version 2.2) \[[@pone.0129181.ref037]\] and Microsoft Excel 2010 \[[@pone.0129181.ref014]\].

Finally, post-hoc descriptive analysis according to condition and type of MMT was conducted.

Results {#sec009}
=======

Characteristics of Included Meta-Analyses {#sec010}
-----------------------------------------

A total of 816 references were initially recognized. Post-duplicate removal, 510 (62.5%) remained. Of the 510 screened, 10 meta-analyses, all using the aggregate data approach, met all study eligibility criteria \[[@pone.0129181.ref038]--[@pone.0129181.ref047]\]. Search precision was 0.02 whilst the NNR was 51. Ineligible studies were excluded based on an inappropriate study design (81.6%) as well as inappropriate outcome (11.6%), intervention (5.0%), population (1.6%), and comparison (0.2%). Two meta-analyses in which results were reported using the original metric were converted to SMDs \[[@pone.0129181.ref043],[@pone.0129181.ref046]\]. [Fig 1](#pone.0129181.g001){ref-type="fig"} illustrates the search process while the references for the 500 excluded studies, including the reasons for rejection, can be found in [S2 File](#pone.0129181.s002){ref-type="supplementary-material"}. As can be seen in [Table 1](#pone.0129181.t001){ref-type="table"}, three studies were conducted in Germany, all by the same investigative team \[[@pone.0129181.ref039]--[@pone.0129181.ref041]\], three in China \[[@pone.0129181.ref043],[@pone.0129181.ref046],[@pone.0129181.ref047]\], and one each in either the United States \[[@pone.0129181.ref045]\], United Kingdom \[[@pone.0129181.ref044]\], Netherlands \[[@pone.0129181.ref038]\], or Taiwan \[[@pone.0129181.ref042]\]. Five of the 10 meta-analyses reported receiving funding for their work \[[@pone.0129181.ref038]--[@pone.0129181.ref040],[@pone.0129181.ref044],[@pone.0129181.ref045]\] while nine reported no competing interests \[[@pone.0129181.ref038]--[@pone.0129181.ref041],[@pone.0129181.ref043]--[@pone.0129181.ref047]\]. Another study did not provide any information on competing interests \[[@pone.0129181.ref042]\]. All of the meta-analyses focused on participants with specific conditions \[[@pone.0129181.ref038]--[@pone.0129181.ref047]\]. With respect to gender, four meta-analyses were limited to women with breast cancer \[[@pone.0129181.ref038],[@pone.0129181.ref039],[@pone.0129181.ref042],[@pone.0129181.ref047]\] while the remaining six included both men and women \[[@pone.0129181.ref040],[@pone.0129181.ref041],[@pone.0129181.ref043]--[@pone.0129181.ref046]\]. A lack of data was provided for race and ethnicity. For MMT, seven of the 10 meta-analyses were limited to yoga \[[@pone.0129181.ref038]--[@pone.0129181.ref042],[@pone.0129181.ref044],[@pone.0129181.ref047]\], while one each was limited to either tai chi \[[@pone.0129181.ref043]\], qigong \[[@pone.0129181.ref045]\], or both \[[@pone.0129181.ref046]\]. Based on the availability of data, the length of the interventions within each study included in the meta-analyses ranged from 1 to 24 weeks, frequency from 1 to 9 times per week and duration from 30 to 120 minutes per session. The mean length of the interventions for each meta-analysis ranged from 8 to 16 weeks ($\overline{\text{X}}$ ± SD, 11.9 ± 2.6, Median = 12), frequency from 2 to 6 times per week ($\overline{\text{X}}$ ± SD, 3.2 ± 1.5, Median = 3), and duration from 53 to 80 minutes per session ($\overline{\text{X}}$ ± SD, 68.9 ± 10.3, Median = 71). Supervised as well unsupervised MMT sessions occurred at a facility and/or home. Data on compliance to the MMT sessions were lacking. For the four meta-analyses that provided information, no serious adverse events were identified from the studies that included the assessment of HRQOL \[[@pone.0129181.ref038]--[@pone.0129181.ref041]\]. A total of 12 different instruments were used to assess HRQOL and included both generic and disease-specific questionnaires \[[@pone.0129181.ref038]--[@pone.0129181.ref041]\].

![Flow Diagram for the selection of studies.\
\*, number of reasons exceeds the number of studies because some studies were excluded for more than one reason.](pone.0129181.g001){#pone.0129181.g001}
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###### General characteristics of included meta-analyses.

![](pone.0129181.t001){#pone.0129181.t001g}

  Reference                                    Year   Country          Studies   Participants                                                                                                                                    Interventions                                                                                                                                                                                                                                                     HRQOL Assessment
  -------------------------------------------- ------ ---------------- --------- ----------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------
  Buffart et al.\[[@pone.0129181.ref038]\]     2012   Netherlands      7         528 women with breast cancer, 28--75 years of age ($\overline{X} \pm$ SD, 52.0 ± 4.5)[\*](#t001fn002){ref-type="table-fn"}                      Supervised/unsupervised yoga interventions lasting 6--24 weeks ($\overline{X} \pm$ SD, 10 ± 7), frequency of 3-9x week ($\overline{X} \pm$ SD, 6 ± 2), duration of 60--90 minutes per session ($\overline{X} \pm$ SD, 68 ± 13)                                    SF-36, EORTC QLQ-C30, FACT G, FLIC
  Cramer et al.\[[@pone.0129181.ref039]\]      2012   Germany          4         274 women with breast cancer (155 yoga, 119 control), age, $\overline{X} \pm$ SD, 57.1 ± 3.1)                                                   Yoga interventions lasting 10--24 weeks ($\overline{X} \pm$ SD, 15 [+]{.ul} 8), frequency of 1 to 4x week ($\overline{X} \pm$ SD, 2 ± 2), duration of 30--90 minutes per session,($\overline{X} \pm$ SD, 71 ± 28)                                                 SF-12, FACT B, FACT G, FLIC, FACT-Sp
  Cramer et al.\[[@pone.0129181.ref040]\]      2013   Germany          2         98 men and women (48 yoga, 50 control), all with schizophrenia, age ($\overline{X} \pm$ SD, 36.1 ± 9.5 years                                    Yoga interventions lasting 8 weeks, frequency of 2-3x week ($\overline{X} \pm$ SD, 3 ± 2), duration of 45 to 60 minutes per session, ($\overline{X} \pm$ SD, 53 ± 11)                                                                                             GQOLI-74, WHO-QOL-BREF
  Cramer et al.\[[@pone.0129181.ref041]\]      2013   Germany          4         388 men and women with low back pain (187 yoga, 201 control), 44 to 49 years of age ($\overline{X} \pm$ SD, 46.0 ± 1.9) years)                  Supervised and unsupervised yoga interventions lasting 1--12 weeks ($\overline{X} \pm$ SD, 9 ± 6) frequency ≤ 7x week, duration of 30 to 75 minutes per session                                                                                                   SF-12, SF-36, EQ5D, WHO-QOL-BREF
  Lin et al.\[[@pone.0129181.ref042]\]         2011   Taiwan           3         191 women with breast cancer (115 yoga, 76 control), 51 to 56 years of age ($\overline{X} \pm$ SD, 54.0 ± 2.0 years)                            Supervised and unsupervised yoga interventions lasting 7--12 weeks ($\overline{X} \pm$ SD, 10 ± 3), duration of 75--90 minutes per session,($\overline{X} \pm$ SD, 80 ± 9)                                                                                        SF-12, FACT B, FACT G, EORTC QLQ-C30
  Pan et al.\[[@pone.0129181.ref043]\]         2013   China            3         182 men and women with heart failure (90 tai chi, 92 control), 64 to 70 years of age ($\overline{X} \pm$ SD, 66.8 ± 3.0 years)                  Tai chi interventions lasting 12--16 weeks ($\overline{X} \pm$ SD, 13 ± 2), frequency of 2x week, duration of 55 to 60 minutes per session, ($\overline{X} \pm$ SD, 58 ± 3)                                                                                       MLHF
  Shneerson et al.\[[@pone.0129181.ref044]\]   2013   United Kingdom   3         153 men and women with cancer, primarily breast cancer (87 yoga, 66 control), 50 to 63 years of age ($\overline{X} \pm$ SD, 57.0 ± 5.0 years)   Supervised yoga interventions lasting 7--24 weeks ($\overline{X} \pm$ SD, 12 ± 7), at least one session per week, duration of 60--90 minutes per session                                                                                                          FACT B, FACT G, EORTC QLQ-C30
  Wang et al.\[[@pone.0129181.ref045]\]        2013   United States    2         172 men and women with diabetes, (120 qi gong, 52 control), 37 to 69 years of age ($\overline{X} \pm$ SD, 57.9 ± 0.1 years)                     qigong interventions lasting 16 weeks                                                                                                                                                                                                                             DSQL
  Zeng et al.\[[@pone.0129181.ref046]\]        2014   China            5         405 men and women with cancer, (200 tai chi or qigong, 205 control), ≥ 18 years of age                                                          Supervised and unsupervised tai chi and qigong interventions lasting 6--24 weeks ($\overline{X} \pm$ SD, 12 [+]{.ul} 7), frequency of 2-7x week ($\overline{X} \pm$ SD, 4 [+]{.ul} 2), duration of 40--120 minutes per session ($\overline{X} \pm$ SD, 78 ± 46)   SF-36^a^, FACT G
  Zhang et al.\[[@pone.0129181.ref047]\]       2012   China            4         270 women with breast cancer, (154 yoga, 116 control), 53 to 59 years of age ($\overline{X} \pm$ SD, 55.6 ± 3.0 years)                          Yoga interventions lasting 6--24 weeks ($\overline{X} \pm$ SD, 13 ± 8), frequency of 1-5x week ($\overline{X} \pm$ SD, 2 ± 2), duration of 60--90 minutes per session ($\overline{X} \pm$ SD, 75 ± 12)                                                            FACT B, FACT G

Notes: $\overline{X} \pm$ SD, mean [+]{.ul} standard deviation; Description of meta-analyses limited to those studies nested within each meta-analysis that met all eligibility criteria for the current study; Data presented limited to what was reported or could be calculated from reported data; Number of participants limited to those in which a SMD was calculated; SF-36, Medical Outcomes Short-form Health Survey-36; EORTC QLQ-C30, European Organization for the Research and Treatment of Cancer-Quality of Life; FACT G, Functional Assessment of Cancer Therapy-General; FLIC, Functional Living Index for Cancer; SF-12, Medical Outcomes Short-form Health Survey-12; FACT B, Functional Assessment of Cancer Therapy-Breast; FACT-Sp, Functional Assessment of Cancer Therapy--Spirituality; GQOLI-74, General Quality of Life Inventory; WHO-QOL-BREF, WHO Quality of Life-BREF quality of life assessment; EQ5D, EuroQol 5 Digit Questionnaire; MLHF, Minnesota Living With Heart Failure Questionnaire; DSQL, Diabetes Specific Quality-of-Life Scale; SF-36^a^ results also reported but excluded because results were for 8 subdomains versus physical and mental component scores.

\*, separate sample sizes not available for yoga and control groups.

Methodological Quality and Impact {#sec011}
---------------------------------

[S1 Table](#pone.0129181.s003){ref-type="supplementary-material"} shows the results for each meta-analysis using the AMSTAR instrument. Across all categories, scores ranged from 50% to 70% ($\overline{\text{X}}$ ± SD, 66.3% ± 6.6%, Median = 70%). All included meta-analyses were considered to have satisfied five of the 11 criteria: (1) "a priori" design, (2) characteristics of studies table, (3) quality/risk of bias assessment, (4) inclusion of quality/risk of bias assessment in formulating conclusions, and (5) methods used for pooling results \[[@pone.0129181.ref038]--[@pone.0129181.ref047]\]. In contrast, none of the included meta-analyses adequately addressed the question regarding conflict of interest, all because they did not report information on potential sources of support from each of the studies included in their meta-analysis \[[@pone.0129181.ref038]--[@pone.0129181.ref047]\]. Similarly, none of the meta-analyses adequately addressed the two questions about including all eligible studies regardless of publication status as well as providing a reference list of eligible and ineligible studies, the latter because none provide a list of ineligible studies, including the reasons for exclusion \[[@pone.0129181.ref038]--[@pone.0129181.ref047]\]. Finally, because of the small number of studies included in each meta-analysis and based on current guidelines that at least 10 effect sizes be available to conduct tests for small-study effects (publication bas, etc.) \[[@pone.0129181.ref035]\], no "Yes" responses were recorded.

With respect to impact, the total number of times that each meta-analysis was cited ranged from 1 to 63 ($\overline{\text{X}}$ ± SD, 20 ± 20, Median = 12). When adjusted for the number of years that each meta-analysis was available, the total number of times that each meta-analysis was cited ranged from 1 to 43 ($\overline{\text{X}}$ ± SD, 12 ± 13, Median = 8).

Data Synthesis {#sec012}
--------------

[Table 2](#pone.0129181.t002){ref-type="table"} and [Fig 2](#pone.0129181.g002){ref-type="fig"} show the overall results for the 10 included systematic reviews with meta-analysis \[[@pone.0129181.ref038]--[@pone.0129181.ref047]\]. The number of SMDs for each HRQOL analysis ranged from 2 to 7 ($\overline{\text{X}}$ ± SD, 3 ± 1, Median = 3) while the number of participants nested within each analysis ranged from 82 to 528 ($\overline{\text{X}}$ ± SD, 269 ± 131, Median = 270). Across all analyses, statistically significant improvements in HRQOL were observed for 15 of the 19 (78.9%) results. Changes in HRQOL ranged from a low of 0.18 (trivial effect) to a high of 2.28 (large effect). For the 15 results that were statistically significant, 10 (66.7%) yielded statistically significant results for heterogeneity based on the Q statistic. In contrast, only 6 of the 15 statistically significant results (46.7%) were considered to display very large inconsistency as indicated by the *I* ^*2*^ statistic. For the nine PI that could be calculated, all included zero (0), i.e., not statistically significant. Publication bias was not examined or calculated because all of the analyses included a sample size of less than 10.

![Forest plot for standardized mean difference effect size changes in HRQOL.\
The black squares represent the pooled standardized mean difference effect size for each analysis while the left and right extremes of the squares represent the corresponding 95% confidence intervals for the pooled standardized mean difference effect size for each analysis. All analyses are based on a random-effects model and not pooled across all analyses because some of the results included the same studies. The numbers in brackets represent reference numbers. Y, Yoga; NT, No Treatment; E, Education; MMT, Meditative Movement Therapies.](pone.0129181.g002){#pone.0129181.g002}
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###### Overall post-treatment standardized mean difference (SMD) effect sizes for HRQOL from included meta-analyses.

![](pone.0129181.t002){#pone.0129181.t002g}

  Reference                                                                  ES/Participants                                                                                                                                                                                                                                                                 
  -------------------------------------------------------------------------- ----------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------- ------------------------------------------------------------- ---- ------ -------------
  Buffart et al.\[[@pone.0129181.ref038]\]                                                                                                                                                                                                                                                                                                                   
  -All studies                                                               7/528             **0.88 (0.25, 1.50)** [\*](#t002fn002){ref-type="table-fn"}                                                                                                         2.75 (0.006)    **44.4 (\<0.001)** [\*\*](#t002fn003){ref-type="table-fn"}    87          
  \- One outlier deleted\[[@pone.0129181.ref059]\]                           6/467             **0.61 (0.16, 1.06)** [\*](#t002fn002){ref-type="table-fn"}                                                                                                         2.50 (0.008)    **16.55 (0.005)** [\*\*](#t002fn003){ref-type="table-fn"}     70          
  \- Two outliers deleted\[[@pone.0129181.ref059],[@pone.0129181.ref060]\]   5/405             **0.37 (0.11, 0.62)** [\*](#t002fn002){ref-type="table-fn"}                                                                                                         2.85 (0.004)    3.40(0.49)                                                    0    0.00   -0.04, 0.78
  Cramer et al.\[[@pone.0129181.ref039]\]                                                                                                                                                                                                                                                                                                                    
  -Short-term effects[^c^](#t002fn006){ref-type="table-fn"}                  4/274             **0.62 (0.04, 1.21)** [\*](#t002fn002){ref-type="table-fn"}                                                                                                         2.08 (0.04)     **14.48 (0.002)** [\*\*](#t002fn003){ref-type="table-fn"}     79   0.28   -1.99, 3.23
  -Short-term effects (Y vs NT)                                              3/212             **0.29 (0.01, 0.57)** [\*](#t002fn002){ref-type="table-fn"}                                                                                                         2.08 (0.04)     0.75 (0.69)                                                   0    0.00   -1.53, 2.11
  Cramer et al.\[[@pone.0129181.ref040]\]                                    2/98              **2.28 (0.42, 4.14)** [\*](#t002fn002){ref-type="table-fn"}                                                                                                         2.40 (0.02)     **9.01 (0.003)** [\*\*](#t002fn003){ref-type="table-fn"}      89   1.62   ---
  Cramer et al.\[[@pone.0129181.ref041]\]                                                                                                                                                                                                                                                                                                                    
  -Short-term effects[^c^](#t002fn006){ref-type="table-fn"}                  4/388             0.41 (-0.10, 0.93)                                                                                                                                                  1.54 (0.12)     **10.7 (0.01)** [\*\*](#t002fn003){ref-type="table-fn"}       72   0.19   NA
  -Short-term effects (Y vs E)[^c^](#t002fn006){ref-type="table-fn"}         3/308             **0.25 (0.02, 0.47)** [\*](#t002fn002){ref-type="table-fn"}                                                                                                         2.17 (0.03)     1.25 (0.54)                                                   0    0.00   -1.21, 1.71
  -Long-term effects (Y vs E)[^d^](#t002fn007){ref-type="table-fn"}          2/287             0.18 (-0.05, 0.41)                                                                                                                                                  1.52 (0.13)     0.10 (0.76)                                                   0    0.00   NA
  Lin et al.\[[@pone.0129181.ref042]\]                                       3/191             0.29 (-0.01, 0.58)[^**a**^](#t002fn004){ref-type="table-fn"}                                                                                                        1.91 (0.06)     1.34 (0.51)                                                   0    0.00   NA
  Pan et al.\[[@pone.0129181.ref043]\]                                                                                                                                                                                                                                                                                                                       
  -All studies                                                               3/190             **1.03 (0.29, 1.76)** [\*](#t002fn002){ref-type="table-fn"} ^**,**^ [^**a**^](#t002fn004){ref-type="table-fn"} ^**,**^ [^**b**^](#t002fn005){ref-type="table-fn"}   2.75 (0.01)     **9.64 (0.01)** [\*\*](#t002fn003){ref-type="table-fn"}       79   0.33   -7.69, 9.75
  -One study deleted\[[@pone.0129181.ref048]\]                               2/130             1.12 (-0.29, 2.54) [^**a**^](#t002fn004){ref-type="table-fn"} ^**,**^ [^**b**^](#t002fn005){ref-type="table-fn"}                                                    1.55 (0.12)     **8.95 (\<0.001)** [\*\*](#t002fn003){ref-type="table-fn"}    88   0.93   NA
  -One study deleted\[[@pone.0129181.ref049]\]                               2/152             **0.70 (0.14, 1.27)** [\*](#t002fn002){ref-type="table-fn"} ^**,**^ [^**a**^](#t002fn004){ref-type="table-fn"} ^**,**^ [^**b**^](#t002fn005){ref-type="table-fn"}   2.43 (0.02)     **2.66 (0.10)** [\*\*](#t002fn003){ref-type="table-fn"}       62   0.11   ---
  -One study deleted\[[@pone.0129181.ref050]\]                               2/82              **1.41 (0.57, 2.25)[\*](#t002fn002){ref-type="table-fn"}** ^**,**^ [^**a**^](#t002fn004){ref-type="table-fn"} ^**,**^ [^**b**^](#t002fn005){ref-type="table-fn"}    3.29 (0.001)    **2.66 (0.10)** [\*\*](#t002fn003){ref-type="table-fn"}       62   0.23   ---
  Shneerson et al.\[[@pone.0129181.ref044]\]                                 3/153             **0.51 (0.18, 0.84)** [\*](#t002fn002){ref-type="table-fn"}                                                                                                         3.06 (0.002)    0.33 (0.85)                                                   0    0.00   -1.63, 2.65
  Wang et al.\[[@pone.0129181.ref045]\]                                      2/172             **0.58 (0.25, 0.91)** [\*](#t002fn002){ref-type="table-fn"} ^**,**^ [^**a**^](#t002fn004){ref-type="table-fn"}                                                      3.40 (0.0007)   0.16 (0.69)                                                   0    0.00   ---
  Zeng et al.\[[@pone.0129181.ref046]\]                                                                                                                                                                                                                                                                                                                      
  -Tai chi & qigong                                                          5/405             **1.94 (0.59, 3.38)** [\*](#t002fn002){ref-type="table-fn"} ^**,**^ [^**a**^](#t002fn004){ref-type="table-fn"} ^**,**^ [^**b**^](#t002fn005){ref-type="table-fn"}   2.80 (0.005)    **116.9 (\<0.001)** [\*\*](#t002fn003){ref-type="table-fn"}   97   2.33   -3.42, 7.30
  -Qigong only                                                               4/395             **1.79 (0.26, 3.32)** [\*](#t002fn002){ref-type="table-fn"} ^**,**^ [^**a**^](#t002fn004){ref-type="table-fn"} ^**,**^ [^**b**^](#t002fn005){ref-type="table-fn"}   2.29 (0.02)     **114.4 (\<0.001)** [\*\*](#t002fn003){ref-type="table-fn"}   97   2.38   -5.65, 9.23
  Zhang et al.\[[@pone.0129181.ref047]\]                                     4/270             **0.27 (0.02, 0.52)** [\*](#t002fn002){ref-type="table-fn"}                                                                                                         2.15 (0.03)     0.88 (0.83)                                                   0    0.00   -0.28, 0.82

Notes: No., Number; ES, effect size; SMD, standardized mean difference effect size; 95% CI, 95% confidence intervals; Z(p), Z-value and probability value for Z; Q(p), Cochran's Q statistic and associated alpha (p) value for Q; *I* ^*2*^, I-squared statistic for inconsistency; T^2^, tau-squared; PI, prediction intervals, based on a random-effects model; Y vs NT, yoga versus no treatment; Y vs E, yoga versus education;---, Data not provided or insufficient data to calculate; SMD (95% CI) based on random-effects model; NA, not applicable; **Boldfaced**

\***,** statistically significant non-overlapping confidence intervals

\*\*, statistically significant at an alpha level ≤ 0.10

^a^, Data reverse-scaled to be consistent with other studies in which a positive SMD was indicative of improvements in HRQOL

^b^, Data converted from original metric to standardized mean difference effect size for comparison purposes

^c^, short-term effects, HRQOL assessed closest to the end of the intervention

^d^, long-term effects, HRQOL assessed closest to 12 months after randomization

When examined according to condition, the six studies that focused on cancer participants, primarily breast cancer \[[@pone.0129181.ref038],[@pone.0129181.ref039],[@pone.0129181.ref042],[@pone.0129181.ref044],[@pone.0129181.ref046],[@pone.0129181.ref047]\], yielded nine of 10 (90.0%) statistically significant findings for HRQOL. Across all 10 results, SMD effect sizes ranged from 0.27 (small effect) to 1.94 (large effect). Statistically significant heterogeneity (Q) was observed for five of the 10 (50%) findings while very large inconsistency was observed for four (40%). For schizophrenia, a large and statistically significant SMD along with statistically significant heterogeneity and very large inconsistency was observed for HRQOL \[[@pone.0129181.ref040]\]. For low back pain, a non-significant SMD was observed for short-term effects, regardless of comparison group, as well as long-term effects when the comparison group was limited to education \[[@pone.0129181.ref041]\]. In contrast, a small and statistically significant effect was observed for HRQOL along with no statistically significant heterogeneity and inconsistency when results were limited to short-term effects and an education comparison group. For heart failure patients, a large, statistically significant SMD effect size as well as statistically significant heterogeneity and very large amount of inconsistency was observed for HRQOL across all studies \[[@pone.0129181.ref043]\]. Results were no longer statistically significant when one study was deleted \[[@pone.0129181.ref048]\] while improvements in HRQOL remained statistically significant along with statistically significant heterogeneity and large inconsistency when either of the other two studies were deleted \[[@pone.0129181.ref049],[@pone.0129181.ref050]\]. Finally, for the one study focused on participants with diabetes, a moderate and statistically significant improvement in HRQOL was observed along with no statistically significant heterogeneity or inconsistency \[[@pone.0129181.ref045]\].

When examined according to type of intervention, 10 of 12 results (83.3%) from seven meta-analyses yielded statistically significant SMD improvements in HRQOL when yoga was used as the intervention \[[@pone.0129181.ref038]--[@pone.0129181.ref042],[@pone.0129181.ref044],[@pone.0129181.ref047]\]. Across all 12 results, SMDs for HRQOL ranged from a low of 0.18 (trivial effect) to a high of 2.28 (large effect). For those results that were statistically significant, five of 10 (50%) yielded statistically significant heterogeneity while three (30%) yielded very large inconsistency. The overall results for the meta-analysis that was limited to tai chi yielded a large and statistically significant improvement in HRQOL along with statistically significant heterogeneity and very large inconsistency \[[@pone.0129181.ref043]\]. However, when each of the three included studies was deleted from the meta-analysis once \[[@pone.0129181.ref048]--[@pone.0129181.ref050]\], changes ranged from a non-significant SMD of 1.21 to a statistically significant improvement in HRQOL of 1.41 (large effect) that was accompanied by statistically significant heterogeneity and large inconsistency. For the meta-analysis that included qigong as the only intervention and was limited to two studies \[[@pone.0129181.ref045]\], a statistically significant SMD improvement of 0.58 (moderate effect) was reported for HRQOL along with no statistically significant heterogeneity or inconsistency. Finally, the meta-analysis that included either tai chi or qigong resulted in a large, statistically significant improvement of 1.94 for HRQOL as well as statistically significant heterogeneity and very large inconsistency \[[@pone.0129181.ref046]\]. When limited to qigong studies only, similar results were obtained.

Number needed-to-treat estimates for those results that were statistically significant can be found in [Table 3](#pone.0129181.t003){ref-type="table"}. As can be seen, the NNT for improving HRQOL ranged from 2 to 10 across all eligible meta-analyses \[[@pone.0129181.ref038]--[@pone.0129181.ref041],[@pone.0129181.ref043]--[@pone.0129181.ref047]\]. When limited to selected conditions, the six studies that focused on cancer participants, primarily breast cancer patients \[[@pone.0129181.ref038],[@pone.0129181.ref039],[@pone.0129181.ref042],[@pone.0129181.ref044],[@pone.0129181.ref046],[@pone.0129181.ref047]\], yielded NNT estimates ranging from 2 to 10. For the remaining meta-analyses, NNT values were 2 (schizophrenia) \[[@pone.0129181.ref040]\], 10 (low back pain) \[[@pone.0129181.ref041]\], 2 to 3 (heart failure) \[[@pone.0129181.ref043]\], and 4 (diabetes) \[[@pone.0129181.ref045]\]. When partitioned according to type of intervention, the NNT ranged from 2 to 10 for yoga \[[@pone.0129181.ref038]--[@pone.0129181.ref041],[@pone.0129181.ref044],[@pone.0129181.ref047]\], 2 to 3 for tai chi only \[[@pone.0129181.ref043]\], 2 and 4 for qigong only \[[@pone.0129181.ref045],[@pone.0129181.ref046]\], and 2 for tai chi and qigong combined \[[@pone.0129181.ref046]\].

Percentile improvements for statistically significant meta-analytic results are also shown in [Table 3](#pone.0129181.t003){ref-type="table"} and [Fig 3](#pone.0129181.g003){ref-type="fig"}. Across all eligible meta-analyses \[[@pone.0129181.ref038]--[@pone.0129181.ref041],[@pone.0129181.ref043]--[@pone.0129181.ref047]\], percentile improvements in HRQOL ranged from 9.9 to 48.9. When limited to selected conditions, percentile improvements for the six studies that focused on cancer participants, primarily breast cancer patients \[[@pone.0129181.ref038],[@pone.0129181.ref039],[@pone.0129181.ref042],[@pone.0129181.ref044],[@pone.0129181.ref046],[@pone.0129181.ref047]\], ranged from 10.6 to 46.3. For the remaining meta-analyses, percentile improvements were 48.9 for schizophrenia \[[@pone.0129181.ref040]\], 9.9 for low back pain \[[@pone.0129181.ref041]\], 25.8 to 42.1 for heart failure \[[@pone.0129181.ref043]\] and 21.9 for diabetes \[[@pone.0129181.ref045]\]. When examined according to type of intervention, percentile improvements ranged from 9.9 to 48.9 for yoga \[[@pone.0129181.ref038]--[@pone.0129181.ref041],[@pone.0129181.ref044],[@pone.0129181.ref047]\], 25.8 to 42.1 for tai chi only \[[@pone.0129181.ref043]\], 21.9 and 46.3 for qigong only \[[@pone.0129181.ref045],[@pone.0129181.ref046]\], and 47.4 for tai chi and qigong combined \[[@pone.0129181.ref046]\].

![Forest plot for percentile changes in HRQOL.\
The black squares represent the pooled percentile improvement for each analysis while the left and right extremes of the squares represent the corresponding 95% confidence intervals for percentile improvement for each analysis. All analyses are based on a random-effects model and not pooled across all analyses because some of the results included the same studies. Confidence intervals for each result are not perfectly symmetric because they were calculated separately from the standardized mean difference effect size and corresponding 95%confidence intervals. The numbers in brackets represent reference numbers. Y, Yoga; NT, No Treatment; E, Education; MMT, Meditative Movement Therapies.](pone.0129181.g003){#pone.0129181.g003}
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###### NNT and percentile improvement in HRQOL.

![](pone.0129181.t003){#pone.0129181.t003g}

  Reference                                                                  NNT (95% CI)   U~3~ Index (95% CI)[^a^](#t003fn002){ref-type="table-fn"}
  -------------------------------------------------------------------------- -------------- -----------------------------------------------------------
  Buffart et al.\[[@pone.0129181.ref038]\]                                                  
  \- All studies                                                             3 (2, 10)      31.1 (9.9, 43.3)
  \- One outlier deleted\[[@pone.0129181.ref059]\]                           4 (2, 16)      22.9 (6.4, 35.5)
  \- Two outliers deleted\[[@pone.0129181.ref059],[@pone.0129181.ref060]\]   6 (4, 23)      14.4 (4.4, 23.2)
  Cramer et al.\[[@pone.0129181.ref039]\]                                                   
  \- Short-term effects[^b^](#t003fn003){ref-type="table-fn"}                4 (2, 65)      23.2 (1.6, 38.7)
  \- Short-term effects (Y vs NT)[^b^](#t003fn003){ref-type="table-fn"}      8 (4, 262)     11.4 (0.4, 21.6)
  Cramer et al.\[[@pone.0129181.ref040]\]                                    2 (1, 6)       48.9 (16.3, 50)
  Cramer et al.\[[@pone.0129181.ref041]\]                                                   
  \- Short-term effects                                                      NA             NA
  \- Short-term effects (Y vs E)[^b^](#t003fn003){ref-type="table-fn"}       10 (5, 131)    9.9 (0.8, 18.1)
  \- Long-term effects (Y vs E)[^c^](#t003fn004){ref-type="table-fn"}        NA             NA
  Lin et al.\[[@pone.0129181.ref042]\]                                       NA             NA
  Pan et al.\[[@pone.0129181.ref043]\]                                                      
  \- All studies                                                             2 (2, 8)       34.8 (11.4, 46.1)
  \- One study deleted\[[@pone.0129181.ref048]\]                             NA             NA
  \- One study deleted\[[@pone.0129181.ref049]\]                             3 (2, 18)      25.8 (5.6, 39.8)
  \- One study deleted\[[@pone.0129181.ref050]\]                             2 (2, 4)       42.1 (21.6, 48.8)
  Shneerson et al.\[[@pone.0129181.ref044]\]                                 5 (3, 14)      19.5 (7.1, 30.0)
  Wang et al.\[[@pone.0129181.ref045]\]                                      4 (3, 10)      21.9 (9.9, 31.9)
  Zeng et al.\[[@pone.0129181.ref046]\]                                                     
  -Tai chi & qigong                                                          2 (1, 4)       47.4 (22.2, 50.0)
  \- Qigong only                                                             2 (1, 9)       46.3 (10.3, 50)
  Zhang et al.\[[@pone.0129181.ref047]\]                                     9 (4, 131)     10.6 (0.8, 19.8)

Notes: NNT, number needed to-treat, calculated from SMD and 95% confidence intervals for SMD; 95% CI, 95% confidence intervals; Y vs NT, yoga versus no treatment; Y vs E, yoga versus education; NA, not applicable (overlapping 95% confidence intervals for pooled SMD).

^a^, Cohen's U~3~ Index\[[@pone.0129181.ref033]\]

^b^, short-term effects, HRQOL assessed closest to the end of the intervention

^c^, long-term effects, HRQOL assessed closest to 12 months after randomization

Discussion {#sec013}
==========

Findings {#sec014}
--------

The overall findings of the current study suggest that MMT may have the potential to improve HRQOL in adults with selected conditions. This observation is reinforced by (1) the non-overlapping confidence intervals for the majority (78.9%) of results, (2) low NNT (2 to 10), (3) percentile improvements as a result of MMT (9.9 to 48.9), and (3) good overall quality (median AMSTAR rating = 70%). In contrast, the potentially positive effects of MMT on HRQOL in adults with selected conditions may be weakened by (1) statistically significant heterogeneity for a majority (66.7%) of the positive findings, (2) large to very large inconsistency for more than half (52.6%) of the meta-analyses and (3) overlapping prediction intervals for all of the statistically significant findings.

While the majority of results yielded statistically significant improvements in HRQOL, the magnitude of change varied by 92% across the included conditions (breast cancer, schizophrenia, low back pain, heart failure, diabetes) and interventions (yoga, tai chi, qi gong) \[[@pone.0129181.ref038]--[@pone.0129181.ref047]\]. Consequently, the NNT and percentile changes also varied widely since they were based on the SMD change in HRQOL. However, whether these wide-ranging changes are the result of the condition, intervention, or some other factor(s), or combination of factors, is not known.

The overall results of the included studies are similar to the effects of traditional types of exercise (aerobic, strength training, etc.) in adults with similar conditions. For example, a meta-analysis of 12 randomized controlled trials of physical exercise (aerobic, strength training, etc.) which did not include any MMT, found a statistically significant SMD improvement of 0.30 (95% CI, 0.12 to 0.48) in HRQOL among breast cancer patients and survivors \[[@pone.0129181.ref051]\]. This compares to changes in HRQOL ranging from 0.27 to 1.94 for the six breast cancer MMT meta-analyses included in the current study \[[@pone.0129181.ref038],[@pone.0129181.ref039],[@pone.0129181.ref042],[@pone.0129181.ref044],[@pone.0129181.ref046],[@pone.0129181.ref047]\]. For those with schizophrenia or symptoms of schizophrenia, a previous systematic review that was limited to one study found greater increases in HRQOL (SMD = 0.59) when yoga was compared directly to exercise (walking, jogging, etc,) \[[@pone.0129181.ref052]\]. In comparison, an intervention minus control SMD improvement of 2.28 was found for schizophrenic patients as a result of yoga in the current investigation \[[@pone.0129181.ref040]\]. Another previous meta-analysis of nine randomized controlled trials in 779 patients with heart failure reported a statistically significant SMD improvement of 0.63 in HRQOL as a result of aerobic and strength training exercise

\[[@pone.0129181.ref053]\]. For the current systematic review of previous meta-analyses, a SMD improvement of 1.03 was reported for HRQOL for the one meta-analysis that included heart failure patients \[[@pone.0129181.ref043]\]. Finally, while the investigative team is not aware of any previous meta-analytic research that has examined the effects of exercise on HRQOL in adults with low back pain, a meta-analysis among participants with type 2 diabetes found no statistically significant difference in HRQOL as a result of aerobic exercise for the one trial that was included in their systematic review \[[@pone.0129181.ref054]\]. In contrast, the one meta-analysis included in the current study found a statistically significant SMD improvement of 0.58 in HRQOL as a result of qigong in participants with diabetes \[[@pone.0129181.ref045]\].

Based on the previous information, it appears that improvements in HRQOL as a result of MMT are equal to or greater than traditional exercise interventions among adults with breast cancer, schizophrenia, heart failure and diabetes. However, the effects of traditional exercise interventions on HRQOL in adults with low back pain cannot be elucidated given the apparent absence of any previous meta-analytic work in this area. However, when examined irrespective of condition, the results for SMD changes in HRQOL as a result of MMT from the current study (yoga = 0.18 to 2.28, tai chi = 0.70 to 1.41, qigong = 1.79) were larger than those found for a previous meta-analysis of physical activity interventions (0.11) \[[@pone.0129181.ref055]\].

Implications for Research {#sec015}
-------------------------

Based on the current study, conducted according to PRISMA guidelines relevant to systematic reviews of previous systematic reviews with meta-analysis ([S2 Table](#pone.0129181.s004){ref-type="supplementary-material"}), there are at least six inferences for future research using the meta-analytic approach. First, while the median quality of the 10 included meta-analyses was believed to be good \[[@pone.0129181.ref038]--[@pone.0129181.ref047]\], areas of improvement for future meta-analytic research were noted. These include (1) avoidance of publication status as a criterion for eligibility or providing a strong rationale for not doing so, (2) in addition to providing a reference list of included studies, providing a reference list of excluded studies along with reasons for exclusion, and (3) providing a description of potential conflicts of interest, including potential sources of support, for the studies included in each meta-analysis.

Second, the impact of the included meta-analyses based on citation rates appears to be small. One potential reason for this may be that this work is published in journals that do not have a large readership. A second potential reason may be the lack of universal acceptance of MMT over traditional types of activity such as aerobic exercise and strength training. However, the increasing use of MMT in the United States in recent years is promising \[[@pone.0129181.ref002]\].

Third, all 10 of the included studies were aggregate data meta-analyses \[[@pone.0129181.ref038]--[@pone.0129181.ref047]\]. Since an individual-participant data meta-analysis (IPD) has been suggested to be superior to an aggregate data meta-analysis \[[@pone.0129181.ref056]\], the conduct of an IPD meta-analysis for determining the effects of MMT on HRQOL in adults may be warranted. However, such a decision needs to be made while considering factors such as (1) the ability to retrieve IPD from original study investigators, (2) the increased costs associated with conducting an IPD meta-analysis, and (3) any actual benefit that may be attained by conducting an IPD versus aggregate data meta-analysis \[[@pone.0129181.ref057]\].

Fourth, since it's important in meta-analysis to provide practical information for decision-makers (practitioners, policy-makers, etc.), it is suggested that future meta-analytic research on MMT and HRQOL include information such as NNT and/or percentile improvements. While it may also be important to assess the evidence using an instrument such as the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool \[[@pone.0129181.ref023]\], this instrument may be too conservative despite its flexibility, especially for an intervention such as MMT where the chance of adverse events is probably minimal. Thus, the use of an instrument such as GRADE may result in a potentially beneficial treatment being inappropriately withheld.

Fifth, it is suggested that PIs be included to enhance the interpretation of findings with respect to the effects of MMT on HRQOL in adults. The use of such cannot only help to determine outcome effects in a new study but also may be more valid for decision-making \[[@pone.0129181.ref031]\]. However, it's important to realize that as opposed to CIs, PIs are based on random mean effects \[[@pone.0129181.ref031]\].

Sixth, all of the meta-analyses included were limited to a small number of randomized controlled trials in participants with certain conditions (breast cancer, schizophrenia, low back pain, heart failure, diabetes), and with the exception of one study \[[@pone.0129181.ref058]\], a certain type of MMT (yoga, tai chi or qigong). From the investigative team's perspective, a more powerful and applicable study design would be to conduct a larger meta-analysis of randomized controlled trials that is not limited to either the type of MMT or condition and which also includes healthy adults. One can then perform moderator and/or sensitivity analyses to examine for potential differences in HRQOL according to selected conditions and type of MMT.

Based on the results of the current study, two major recommendations for future randomized controlled trials are suggested. First, given that none of the meta-analyses reported data on the cost-effectiveness of the interventions from the included studies \[[@pone.0129181.ref038]--[@pone.0129181.ref047]\], it is assumed that the original studies included in each of the meta-analyses did not provide this information. Assuming the former, future intervention studies addressing the effects of MMT on HRQOL should provide this data. Inclusion of this information is critically important to decision-makers when trying to decide which interventions should be prioritized over others.

Second, the dose-response effects of MMT on HRQOL in adults is not known, including what MMT, if any, may be more beneficial for improving HRQOL in adults. Related to this issue is a need to identify what specific types of yoga, tai chi and qigong may be most beneficial given that there are several different types of MMT nested within each of these three modalities. Knowledge of these factors should lead to better treatment in the population of interest.

Implications for Practice {#sec016}
-------------------------

The results of the current investigation provide important information for practice. First, despite the lack of cost-effectiveness and adverse event data as well as considerable between-study heterogeneity and/or inconsistency for more than half of the reported results, MMT appear to improve HRQOL in the populations studied. While no definitive recommendations can be made and additional research is needed, it would appear both prudent and safe at this time to suggest that HRQOL may be improved by participating in MMT at least 3 times per week for about 71 minutes per session. However, it is important to note that these are general recommendations.

Strengths and Potential Limitations of Current Study {#sec017}
----------------------------------------------------

At least two strengths of the current study were noted. First, the investigative team believes that this is the first systematic review of previous systematic reviews with meta-analysis aimed at determining the effects of MMT on HRQOL in adults, a recent and increasingly necessary method for not only determining the effects of different healthcare interventions, but also for making decisions about the prioritization and use of these interventions \[[@pone.0129181.ref005]\]. As a result, a summary of previous meta-analyses addressing the effects of MMT on HRQOL is now available to those interested in this topic and from which future research, practice and policy-making may be advanced. Second, the additional analyses conducted based on the available data (NNT, percentile improvement, PIs), aided in strengthening the evidence from which conclusions could be made from the included studies \[[@pone.0129181.ref038]--[@pone.0129181.ref047]\]. The inclusion of PIs also provides future researchers with data for assisting them in the planning and conduct of randomized controlled studies aimed at determining the effects of MMT on HRQOL in adults.

In addition to the strengths of the current study, at least three *possible* limitations were observed. First, the number of studies included in each meta-analysis was small and limited to very narrowly defined populations. Given the former, the strength of the evidence is less than ideal and may not be generalizable to other populations. The former notwithstanding, it's important to note that two is the minimum number of studies necessary for conducting a meta-analysis \[[@pone.0129181.ref003]\]. However, the ability to generalize findings based on such a small number of studies is limited.

Second, it is possible that the results of the included meta-analyses suffered from small-study effects (publication bias, etc.). Unfortunately, the assessment of such was not possible since all of the meta-analysis included less than 10 effect sizes and a minimum of 10 is recommended before any such analyses is performed \[[@pone.0129181.ref035]\].

Third, biases common to the original meta-analyses, for example, ecologic fallacy and Simpson's paradox, as well as the randomized controlled trials included in the meta-analyses, may have existed in the current investigation.

Conclusions {#sec018}
===========

The results of the current review suggest that MMT may improve HRQOL in adults with selected conditions. However, a need exists for a large meta-analysis of randomized controlled trials that is not limited to either the type of MMT or condition, and which also includes healthy adults.
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This table includes the results of the AMSTAR assessment for each item from each study.
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###### PRISMA Checklist.

This table includes the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) checklist relevant to this systematic review of previous systematic reviews with meta-analyses.
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